BRPI0917411A2 - composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit. - Google Patents
composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit.Info
- Publication number
- BRPI0917411A2 BRPI0917411A2 BRPI0917411A BRPI0917411A BRPI0917411A2 BR PI0917411 A2 BRPI0917411 A2 BR PI0917411A2 BR PI0917411 A BRPI0917411 A BR PI0917411A BR PI0917411 A BRPI0917411 A BR PI0917411A BR PI0917411 A2 BRPI0917411 A2 BR PI0917411A2
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- subject
- rassf1a
- cells
- dansyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Natural products C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 title 1
- -1 dansyl carbazole compound Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 102000016397 Methyltransferase Human genes 0.000 abstract 1
- 108060004795 Methyltransferase Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 abstract 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 101150009274 nhr-1 gene Proteins 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Electroluminescent Light Sources (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18905908P | 2008-08-15 | 2008-08-15 | |
| PCT/US2009/004681 WO2010019271A1 (en) | 2008-08-15 | 2009-08-14 | Fluorescent regulators of rassf1a expression and human cancer cell proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0917411A2 true BRPI0917411A2 (pt) | 2015-12-01 |
Family
ID=41279343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0917411A BRPI0917411A2 (pt) | 2008-08-15 | 2009-08-14 | composto de dansil-carbazol, método para tratamento de câncer em um sujeito, método para reduzir atividade de mentiltransferase de dna em uma célula, método para aumentar expressão da associação de dominio da familia 1a(rassf1a) em uma célula, métodos de identificação de célula, método de determinação se uma ou mais células de um sujeito são células cancerosas, composição farmacêutica e kit. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10457639B2 (enExample) |
| EP (2) | EP2484666A1 (enExample) |
| JP (2) | JP2012500197A (enExample) |
| CN (1) | CN102186820B (enExample) |
| AT (1) | ATE547403T1 (enExample) |
| AU (1) | AU2009282451B2 (enExample) |
| BR (1) | BRPI0917411A2 (enExample) |
| CA (1) | CA2734225A1 (enExample) |
| WO (1) | WO2010019271A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| PE20130649A1 (es) | 2010-03-08 | 2013-07-13 | Monsanto Technology Llc | Moleculas polinucleotidicas para regulacion genetica en plantas |
| US8637679B2 (en) | 2011-03-11 | 2014-01-28 | Council Of Scientific And Industrial Research | Process for the isolation of organic compounds useful for the treatment of cancer |
| EP3434779A1 (en) | 2011-09-13 | 2019-01-30 | Monsanto Technology LLC | Methods and compositions for weed control |
| WO2013040116A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
| EP2755466A4 (en) | 2011-09-13 | 2015-04-15 | Monsanto Technology Llc | METHOD AND COMPOSITIONS FOR WEED CONTROL |
| CN103957697B (zh) | 2011-09-13 | 2017-10-24 | 孟山都技术公司 | 用于杂草控制的方法和组合物 |
| US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| MX343072B (es) | 2011-09-13 | 2016-10-21 | Monsanto Technology Llc | Metodos y composiciones para controlar malezas. |
| US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10240162B2 (en) | 2012-05-24 | 2019-03-26 | A.B. Seeds Ltd. | Compositions and methods for silencing gene expression |
| UA118841C2 (uk) | 2013-01-01 | 2019-03-25 | Ей.Бі. СІДС ЛТД. | Спосіб формування рослини, яка має підвищену стійкість до комахи-шкідника |
| US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
| EP2967082A4 (en) | 2013-03-13 | 2016-11-02 | Monsanto Technology Llc | METHOD AND COMPOSITIONS FOR WEED CONTROL |
| WO2014164761A1 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
| WO2014151317A1 (en) * | 2013-03-15 | 2014-09-25 | Rush University Medical Center | Methods for treating cancer |
| US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
| JP6668236B2 (ja) | 2013-07-19 | 2020-03-18 | モンサント テクノロジー エルエルシー | Ｌｅｐｔｉｎｏｔａｒｓａ防除用組成物及びその方法 |
| MX390055B (es) | 2013-11-04 | 2025-03-20 | Monsanto Technology Llc | Composiciones y metodos para controlar infestaciones de plagas y parasitos de los artropodos. |
| UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
| CN105979770B (zh) | 2014-01-15 | 2019-07-05 | 孟山都技术公司 | 用于使用epsps多核苷酸的杂草控制的方法和组合物 |
| BR112016022711A2 (pt) | 2014-04-01 | 2017-10-31 | Monsanto Technology Llc | composições e métodos para controle de pragas de inseto |
| WO2015200223A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
| US11807857B2 (en) | 2014-06-25 | 2023-11-07 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| AU2015296700B2 (en) | 2014-07-29 | 2021-10-21 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
| US10968449B2 (en) | 2015-01-22 | 2021-04-06 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
| US10883103B2 (en) | 2015-06-02 | 2021-01-05 | Monsanto Technology Llc | Compositions and methods for delivery of a polynucleotide into a plant |
| EP3302030A4 (en) | 2015-06-03 | 2019-04-24 | Monsanto Technology LLC | METHOD AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS IN PLANTS |
| US10173978B2 (en) * | 2015-08-05 | 2019-01-08 | Georgetown University | Small molecule androgen receptor inhibitors and methods of use thereof |
| US11464750B2 (en) | 2017-06-12 | 2022-10-11 | Shohei Miyata | Anticancer agent and use thereof |
| CN107266356B (zh) * | 2017-07-25 | 2020-06-26 | 山西省生物研究院有限公司 | 一种作为自分泌运动因子抑制剂的咔唑类化合物及其制备方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2235815A1 (de) * | 1972-07-21 | 1974-01-31 | Bayer Ag | Polyazofarbstoffe |
| WO1988001213A1 (en) | 1986-08-18 | 1988-02-25 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ241954A (en) | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
| GB9215361D0 (en) | 1992-07-20 | 1992-09-02 | Wellcome Found | Heterocyclic compounds |
| WO1995003279A1 (en) | 1993-07-26 | 1995-02-02 | Eisai Co., Ltd. | Sulfonamide and sulfonic ester derivatives each having tricyclic hetero ring |
| JP3690825B2 (ja) * | 1993-07-26 | 2005-08-31 | エーザイ株式会社 | 三環式ヘテロ環含有スルホンアミドおよびスルホン酸エステル誘導体 |
| CA2186412A1 (en) | 1995-10-31 | 1997-05-01 | Katherine S. Takaki | Ethylamino carbazole melatonergic agents |
| WO1999032463A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS |
| WO2000063171A1 (en) * | 1999-04-20 | 2000-10-26 | Meiji Seika Kaisha, Ltd. | Tricyclic compounds |
| CA2394778A1 (en) | 1999-12-16 | 2002-06-14 | Shiro Miyoshi | Novel substituted tricyclic compounds |
| WO2001083452A1 (en) | 2000-04-28 | 2001-11-08 | Asahi Kasei Kabushiki Kaisha | Novel tricyclic compounds |
| US6506901B2 (en) * | 2000-07-17 | 2003-01-14 | Wyeth | Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists |
| EP1847263A3 (en) | 2000-12-18 | 2009-08-26 | Institute of Medicinal Molecular Design, Inc. | Inhibitors against the production and release of inflammatory cytokines |
| AU2002228316A1 (en) * | 2001-01-29 | 2002-08-12 | Insight Strategy And Marketing Ltd | Carbazole derivatives and their uses as heparanase inhibitors |
| JPWO2002074306A1 (ja) | 2001-03-19 | 2004-07-08 | 旭化成ファーマ株式会社 | 脂肪肝治療薬 |
| GB0319151D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Novel compounds |
| US20100063126A1 (en) | 2004-06-29 | 2010-03-11 | Jadolabs Gmbh | Carbazole-Derived Pharmaceutical Compositions |
| ATE381540T1 (de) | 2004-08-18 | 2008-01-15 | Ciba Sc Holding Ag | Oximesther-fotoinitiatoren |
| ITMI20051523A1 (it) | 2005-08-03 | 2007-02-04 | Acraf | Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo |
| GB2443588B (en) | 2005-09-01 | 2010-04-21 | Council Scient Ind Res | A pharmaceutical composition useful for the treatment of prostate cancer |
| CN1807413B (zh) * | 2005-09-28 | 2010-05-05 | 中国医学科学院医药生物技术研究所 | 咔唑磺酰胺衍生物及其制备方法 |
| CA2625219A1 (en) * | 2005-10-13 | 2007-04-19 | Orchid Research Laboratories Limited | Heterocyclic compounds as pstat3/il-6 inhibitors |
| WO2008051523A2 (en) | 2006-10-23 | 2008-05-02 | Georgetown University | Carbazole derivatives useful as medicaments in cancer therapy |
| IL186935A0 (en) * | 2006-10-31 | 2008-02-09 | Veridex Llc | Prostate cancer field effect analysis methods and kits |
| CA2710520A1 (en) * | 2007-12-28 | 2009-07-09 | John Wayne Cancer Institute | Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer |
| AU2009228765B2 (en) | 2008-03-24 | 2012-05-31 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
-
2009
- 2009-08-14 AU AU2009282451A patent/AU2009282451B2/en not_active Ceased
- 2009-08-14 CN CN2009801406819A patent/CN102186820B/zh not_active Expired - Fee Related
- 2009-08-14 EP EP20120152000 patent/EP2484666A1/en not_active Withdrawn
- 2009-08-14 EP EP09789145A patent/EP2323982B1/en not_active Not-in-force
- 2009-08-14 WO PCT/US2009/004681 patent/WO2010019271A1/en not_active Ceased
- 2009-08-14 JP JP2011523005A patent/JP2012500197A/ja active Pending
- 2009-08-14 BR BRPI0917411A patent/BRPI0917411A2/pt not_active IP Right Cessation
- 2009-08-14 AT AT09789145T patent/ATE547403T1/de active
- 2009-08-14 US US13/059,183 patent/US10457639B2/en active Active
- 2009-08-14 CA CA2734225A patent/CA2734225A1/en not_active Abandoned
-
2014
- 2014-05-21 JP JP2014105150A patent/JP2014148545A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102186820B (zh) | 2013-08-28 |
| ATE547403T1 (de) | 2012-03-15 |
| HK1158206A1 (en) | 2012-07-13 |
| CA2734225A1 (en) | 2010-02-18 |
| WO2010019271A8 (en) | 2011-03-31 |
| AU2009282451B2 (en) | 2014-02-13 |
| EP2323982B1 (en) | 2012-02-29 |
| EP2484666A1 (en) | 2012-08-08 |
| JP2014148545A (ja) | 2014-08-21 |
| JP2012500197A (ja) | 2012-01-05 |
| US10457639B2 (en) | 2019-10-29 |
| US20110152339A1 (en) | 2011-06-23 |
| AU2009282451A1 (en) | 2010-02-18 |
| WO2010019271A1 (en) | 2010-02-18 |
| CN102186820A (zh) | 2011-09-14 |
| EP2323982A1 (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE547403T1 (de) | Fluoreszente regulatoren der rassf1a-expression und der proliferation humaner krebszellen | |
| Zhou et al. | Inorganic–organic hybrid nanoprobe for NIR‐excited imaging of hydrogen sulfide in cell cultures and inflammation in a mouse model | |
| WO2006138275A3 (en) | Compositions and methods for treating and diagnosing cancer | |
| ATE513832T1 (de) | 8-anilinoimidazopyridine und ihre verwendung als antikrebsmittel und/oder entzündungshemmende mittel | |
| EA201290389A8 (ru) | Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени | |
| PH12013502369A1 (en) | Diazacarbazoles and methods of use | |
| WO2020107002A3 (en) | Methods for expansion of natural killer (nk) cell subset and related compositions and methods | |
| ATE541053T1 (de) | Verfahren und zusammensetzungen zur behandlung von nichtkleinzelligem lungenkrebs | |
| ECSP088598A (es) | Derivados de piridazinona | |
| ZA200701137B (en) | Triazolophthalazines | |
| EP2003196A3 (en) | Compositions and methods for treating and diagnosing cancer | |
| MX2011011488A (es) | Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina. | |
| BRPI0518198B8 (pt) | método ex vivo para tratar uma composição de células hemácias para inativar um patógeno, se presente, bem como composição e kit | |
| MX2010007927A (es) | Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina. | |
| WO2009153774A3 (en) | Compositions and methods for prognosis of ovarian cancer | |
| EP4650006A3 (en) | Use of a kras g12c inhibitor in treating cancers | |
| RU2014138543A (ru) | Репрограммирование эффекторных белковых взаимодействий для исправления эпигенетических дефектов в злокачественной опухоли | |
| BRPI0511138A (pt) | derivados de pirimidina para o tratamento de desenvolvimento celular anormal | |
| ATE502025T1 (de) | Arylcarboxamide und ihre verwendung als antitumormittel | |
| IL198465A0 (en) | Triazabenzo[e]azulene derivatives for the treatment of tumors | |
| BR0303012A (pt) | Avaliação de câncer colorretal | |
| BR0303091A (pt) | Avaliação de câncer colorretal | |
| BRPI0813550B8 (pt) | composto derivado fluorescente de poliaminas, seu processo de síntese e seu uso | |
| Qi et al. | Establishing a patient-derived xenograft model of human myxoid and round-cell liposarcoma | |
| UA96745C2 (en) | PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |